Every day there are advancements in the technology and medical worlds and recently there was another big announcement surrounding the medical world. The FDA approved a new immunotherapy drug by the name of Keytruda. This drug helps stimulate the body’s immune system as a first-line treatment with non-small-cell lung cancer. To learn more read on in this article.
Key Takeaways:
- The Food and Drug Administration approved an immunotherapy drug called Keytruda, which stimulates the body’s immune system, for the first-line treatment of patients with metastatic non-small-cell lung cancer.
- So it seems, the future of cancer care may be in our own immune systems, but how exactly does it work, and what are its pros and cons?
- “Immunotherapy has essentially undergone a sort of revolution in the last decade in the sense that something that was experimental — and there were still questions about what role it would have in the way cancer is treated — is completely turned around, and now it’s clear it’s effective,” Greenberg said.
“The Food and Drug Administration approved an immunotherapy drug called Keytruda, which stimulates the body’s immune system, for the first-line treatment of patients with metastatic non-small-cell lung cancer.”